Sumitomo Pharma Co., Ltd. (TYO:4506)
1,349.00
-41.00 (-2.95%)
Aug 14, 2025, 3:30 PM JST
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 108.00B JPY in the quarter ending June 30, 2025, with 19.11% growth. This brings the company's revenue in the last twelve months to 416.16B, up 26.28% year-over-year. In the fiscal year ending March 31, 2025, Sumitomo Pharma had annual revenue of 398.83B with 26.79% growth.
Revenue (ttm)
416.16B
Revenue Growth
+26.28%
P/S Ratio
1.33
Revenue / Employee
108.60M
Employees
3,832
Market Cap
552.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
Mar 31, 2021 | 515.95B | 33.22B | 6.88% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.22B |
Takeda Pharmaceutical Company | 4,480.25B |
HOYA Corporation | 876.09B |
Daiichi Sankyo Company | 1,924.68B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |